This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Safety of Olanzapine

Charles M. Beasley, Jr., M.D., Gary D. Tollefson, M.D., Ph.D., and Pierre V. Tran, M.D.

Published: March 1, 1997

Article Abstract

Clinical safety data for treatment of acute schizophrenia with olanzapine, a new atypical antipsychoticagent, are summarized. The primary clinical trial safety database included 2500 patients treatedwith olanzapine, 810 with haloperidol, and 236 with placebo. The overall discontinuation rate fromolanzapine treatment was low. Significant adverse events included somnolence, weight gain, andasymptomatic treatment-emergent transaminase elevation. Minimal parkinsonism and akathisia withrare dystonia were noted. No hematotoxicity was noted. The incidence of seizures and sexual dysfunction was rare.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 58

Quick Links: